94 related articles for article (PubMed ID: 24573400)
21. Glycosphingolipid component profiles or human gliomas--correlation to survival time and histopathological malignancy grading.
Becker R; Rohlfs J; Jennemann R; Wiegandt H; Mennel HD; Bauer BL
Clin Neuropathol; 2000; 19(3):119-25. PubMed ID: 14606584
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target.
Barnett JA; Urbauer DL; Murray GI; Fuller GN; Heimberger AB
Clin Cancer Res; 2007 Jun; 13(12):3559-67. PubMed ID: 17575219
[TBL] [Abstract][Full Text] [Related]
23. Expression of cancer testis genes in human brain tumors.
Sahin U; Koslowski M; Türeci O; Eberle T; Zwick C; Romeike B; Moringlane JR; Schwechheimer K; Feiden W; Pfreundschuh M
Clin Cancer Res; 2000 Oct; 6(10):3916-22. PubMed ID: 11051238
[TBL] [Abstract][Full Text] [Related]
24. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
Saikali S; Avril T; Collet B; Hamlat A; Bansard JY; Drenou B; Guegan Y; Quillien V
J Neurooncol; 2007 Jan; 81(2):139-48. PubMed ID: 17004103
[TBL] [Abstract][Full Text] [Related]
25. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
[TBL] [Abstract][Full Text] [Related]
26. Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas.
Wang ZL; Zhang CB; Cai JQ; Li QB; Wang Z; Jiang T
J Exp Clin Cancer Res; 2015 Oct; 34():127. PubMed ID: 26502731
[TBL] [Abstract][Full Text] [Related]
27. Transmembrane-4-L-six-family-1, a potential predictor for poor prognosis, overexpressed in human glioma.
Wang P; Bao W; Zhang G; Cui H; Shi G
Neuroreport; 2015 May; 26(8):455-61. PubMed ID: 25855954
[TBL] [Abstract][Full Text] [Related]
28. Expression of cancer/testis antigens is correlated with improved survival in glioblastoma.
Freitas M; Malheiros S; Stávale JN; Biassi TP; Zamunér FT; de Souza Begnami M; Soares FA; Vettore AL
Oncotarget; 2013 Apr; 4(4):636-46. PubMed ID: 23592437
[TBL] [Abstract][Full Text] [Related]
29. Periostin is a novel therapeutic target that predicts and regulates glioma malignancy.
Mikheev AM; Mikheeva SA; Trister AD; Tokita MJ; Emerson SN; Parada CA; Born DE; Carnemolla B; Frankel S; Kim DH; Oxford RG; Kosai Y; Tozer-Fink KR; Manning TC; Silber JR; Rostomily RC
Neuro Oncol; 2015 Mar; 17(3):372-82. PubMed ID: 25140038
[TBL] [Abstract][Full Text] [Related]
30. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.
Mineo JF; Bordron A; Baroncini M; Maurage CA; Ramirez C; Siminski RM; Berthou C; Dam Hieu P
J Neurooncol; 2007 Dec; 85(3):281-7. PubMed ID: 17571214
[TBL] [Abstract][Full Text] [Related]
31. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells.
Liu G; Yu JS; Zeng G; Yin D; Xie D; Black KL; Ying H
J Immunother; 2004; 27(3):220-6. PubMed ID: 15076139
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of Iroquois Homeobox Gene - IRX1 in human glioma.
Zhang P; Liu N; Xu X; Wang Z; Cheng Y; Jin W; Wang X; Yang H; Liu H; Zhang Y; Tu Y
Mol Med Rep; 2018 Mar; 17(3):4651-4656. PubMed ID: 29328446
[TBL] [Abstract][Full Text] [Related]
33. NOS2 expression in glioma cell lines and glioma primary cell cultures: correlation with neurosphere generation and SOX-2 expression.
Palumbo P; Miconi G; Cinque B; Lombardi F; La Torre C; Dehcordi SR; Galzio R; Cimini A; Giordano A; Cifone MG
Oncotarget; 2017 Apr; 8(15):25582-25598. PubMed ID: 28424427
[TBL] [Abstract][Full Text] [Related]
34. Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients.
Ueda R; Yoshida K; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2007 Apr; 120(8):1704-11. PubMed ID: 17230535
[TBL] [Abstract][Full Text] [Related]
35. Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer.
Mostovenko E; Liu Y; Amirian ES; Tsavachidis S; Armstrong GN; Bondy ML; Nilsson CL
ACS Chem Neurosci; 2018 Jan; 9(1):80-84. PubMed ID: 28657708
[TBL] [Abstract][Full Text] [Related]
36. Functional analysis of KIF20A, a potential immunotherapeutic target for glioma.
Saito K; Ohta S; Kawakami Y; Yoshida K; Toda M
J Neurooncol; 2017 Mar; 132(1):63-74. PubMed ID: 28070829
[TBL] [Abstract][Full Text] [Related]
37. The Application of FOXO1A Expression Predicts Aggressive Behavior and Poor Prognosis in Gliomas.
Huang ZY; Hueng DY; Tsai WC
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):74-82. PubMed ID: 30664534
[TBL] [Abstract][Full Text] [Related]
38. A preliminary study on the expression of tumor-associated glycoprotein-72 in human gliomas.
Wang D; Zhang Y; Li X; Cui J; Wang S
Med Oncol; 2012 Sep; 29(3):2027-31. PubMed ID: 21786013
[TBL] [Abstract][Full Text] [Related]
39. Accessibilome of human glioblastoma: collagen-VI-alpha-1 is a new target and a marker of poor outcome.
Turtoi A; Blomme A; Bianchi E; Maris P; Vannozzi R; Naccarato AG; Delvenne P; De Pauw E; Bevilacqua G; Castronovo V
J Proteome Res; 2014 Dec; 13(12):5660-9. PubMed ID: 25325876
[TBL] [Abstract][Full Text] [Related]
40. Rapid immunohistochemistry based on alternating current electric field for intraoperative diagnosis of brain tumors.
Tanino M; Sasajima T; Nanjo H; Akesaka S; Kagaya M; Kimura T; Ishida Y; Oda M; Takahashi M; Sugawara T; Yoshioka T; Nishihara H; Akagami Y; Goto A; Minamiya Y; Tanaka S;
Brain Tumor Pathol; 2015 Jan; 32(1):12-9. PubMed ID: 24807101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
